Day: October 18, 2021

Posted on

Neeyamo’s Focus on Technology and Innovation Makes It a Potential Leader in the Fosway 9-Grid™ for Cloud HR Solutions

FOSWAY GRID FOR CLOUD HR

FOSWAY GRID FOR CLOUD HR

LOS GATOS, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) — Neeyamo Inc., a market leader in global payroll transformation for multinational organizations, has been positioned as a ‘Potential Leader’ in the Fosway 9-Grid™ for Cloud HR, an independent analysis of the Cloud HR systems market. According to Fosway, a potential leader provides sophisticated solutions with comprehensive suites of capabilities that are well suited to complex organizations.

The Fosway 9-Grid™ is a unique, five-dimensional market analysis model that helps HR buyers demystify supplier decisions for incorporating next-gen HR, Talent, and Learning. The market players and their solutions are evaluated based on their potential to serve the market, performance in the industry, total cost of ownership, market presence, and trajectories for the foreseeable future.

The 9-Grid™ provides an understanding of the market, identifies the high-level actions that can help customer organizations, and aims to provide a practical reference and comparison point for all customer organizations with varying degrees of organizational complexity, fragmentation, and multinationalism.

“We are happy to have made progress in further consolidating our position as a Potential Leader in Fosway Group’s 9-Grid™ for Cloud HR. We are confident that we are firmly on our path to becoming a global leader in the domain we have chosen to operate. The COVID-19 pandemic has accelerated the pace of digitalization and the need for MNEs to hire and pay employees across borders. Neeyamo will be at the forefront of this revolution, building solutions to address multinational enterprises’ evolving global payroll needs. We offer a holistic enterprise global payroll stack that is globally compliant, singularly global, and seamlessly integrated,” states Samuel Isaac, Senior Vice President, Strategy at Neeyamo.

“With its capabilities in long-tail HR and payroll, Neeyamo has recognized and is addressing a key challenge for many global companies,” said David Wilson, CEO, Fosway Group. “Neeyamo has consolidated its position as a Potential Leader by consistently delivering innovation for organizations that operate across a wide range of geographies.”

Fosway 9-Grid™ for Cloud HR and the full report can be accessed here.

About the Fosway 9-Grid™

Fosway Group is Europe’s #1 HR Industry Analyst. The Fosway 9-Grid” provides a unique assessment of the principal learning and talent supply options available to organizations in EMEA.

Now in its sixth year, the analysis is based on extensive independent research and insights from Fosway’s Corporate Research Network of over 250 customer organizations, including BP, HSBC, PwC, RBS, Sanofi, Shell, and Vodafone.

Visit the Fosway website at https://www.fosway.com/ for more information on Fosway Group’s research and services.

About Neeyamo

Neeyamo is a leading platform-based global payroll transformation provider focused on delivering global payroll services to multinational organizations with operations across a long-tail of countries. To know more, visit www.neeyamo.com.

Media Contact – corporate.communications@neeyamo.com

Related Images

Image 1: FOSWAY GRID FOR CLOUD HR

FOSWAY GRID FOR CLOUD HR 2021

This content was issued through the press release distribution service at Newswire.com.

Attachment


Copyright © 2021 GlobeNewswire, Inc.

Posted on

Neuropharmacologist and CRO Veteran Graham Birrell Joins George Clinical to Lead APAC Operations

SYDNEY, Oct. 18, 2021 (GLOBE NEWSWIRE) — Graham Birrell, PhD, MBA, a researcher and neuropharmacologist with significant clinical research experience in the EU and Asia-Pacific region has joined George Clinical, a global scientifically-backed clinical research organization, as Head, Project Operations, APAC.  Birrell will also join the scientific leadership of George Clinical with a neurology focus.  In his new role with George Clinical, Birrell will be based in the Asia Pacific region overseeing the extensive project teams the firm has throughout Australia, New Zealand, China, Taiwan, Malaysia, the Philippines, Singapore and South Korea.

Birrell holds a PhD in neuropharmacology from the University of Edinburgh Medical School. His more than 30 years of biopharmaceutical industry experience includes drug discovery and development including positions with GSK, Pfizer and Servier, clinical operations, project management, regulatory consulting, and business development. Formerly serving as VP, Clinical Development, Travecta Therapeutics, Birrell has also held senior management roles in the UK and Singapore with CROs such as Parexel, ICON, IQVIA and most recently Syneos Health, where he led project management and operations teams of more than 230 staff in Asia Pacific as VP, CNS & Ophthalmology Clinical Development.

“Graham is a natural lead for our diverse APAC operations given his multifaceted background in operations, management and developing business with strategic clients,” said Chief Medical Officer Maria Ali.  “With the burgeoning interest running trials across APAC, Graham will be critical in helping sponsors leverage our best-in-class CRO networks and expertise.”

Over the last two decades Birrell has worked on more than 50 clinical development programs, including the management of 14 Phase II-III global programs for central nervous system (CNS), oncology, rheumatology, diabetes, respiratory, ophthalmology and vaccine therapies which were successfully launched into the market.  As a CRO scientific leader in CNS, Birrell’s experience provides scientific and strategic drug development expertise across a wide range of indications including dementia, movement disorders, stroke, multiple sclerosis, mood disorders, acute and chronic pain, and rare CNS diseases will be greatly valued. He has been an invited speaker at several international conferences and has published two patents and more than 25 scientific papers in major journals.

“My management philosophy starts with surrounding yourself with the best people and ensuring they have access to the resources they need to excel, removing all barriers to communication and collaboration,” Birrell noted.  “I’m excited to serve George Clinical clients and teams across this diverse region and partner with our business teams around the globe as we continue setting the standard in APAC clinical research.”

About George Clinical

George Clinical is a leading global clinical research organization founded in Asia-Pacific driven by scientific expertise and operational excellence. With more than 20 years of experience and more than 300 people managing 38 geographical locations throughout the USA, Asia-Pacific region and Europe, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all trial phases, registration and post-marketing trials.

Contact:          mreabold@georgeclinical.com

Website:         https://www.georgeclinical.com

LinkedIn:         https://www.linkedin.com/company/george-clinical-pty-ltd

Twitter:           https://twitter.com/george_clinical

Facebook:       https://www.facebook.com/georgeclinical

For more information of George Clinical, contact:

Donna McDonnell

M +1-901-229-5345

E dmcdonnell@georgeclinical.com

W georgeclinical.com | georgeinstitute.org

Donna McDonnell George Clinical 901-229-5345 dmcdonnell@georgeclinical.com

Posted on

CoImmune Announces Collaboration with Top US Cancer Center to Accelerate Development of CAR-CIK Therapies to Treat Solid Tumors

DURHAM, N.C., Oct. 18, 2021 (GLOBE NEWSWIRE) — CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced a license and collaboration agreement with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the adaptation of CoImmune’s proprietary allogeneic CAR-CIK technology platform to treat solid tumors. Under the terms of the agreement, CoImmune is acquiring rights to several technologies developed at MSK. MSK and CoImmune will be using the technologies to adapt CoImmune’s CAR-CIK cells to treat various solid tumors.

“In the past year, CoImmune has made very significant progress in the development of our CAR-CIK technology platform,” said Charles Nicolette, chief executive officer of CoImmune. “The outstanding team at MSK represents the ideal partner to position CoImmune as a scientific leader in the CAR-T solid tumor space.”

The chimeric antigen receptor (CAR) modified cytokine induced killer (CIK) cell platform developed by CoImmune is a variation on CAR-T therapy that is designed to enhance efficacy with greatly reduced toxicity. CIK cells are multifunctional, possessing the killing mechanisms of both T cells and NK cells and are much more resistant to inducing GVHD compared to T cells. Also, CoImmune’s proprietary ‘Sleeping Beauty’ gene transfer technology (SB100X) is more efficient than recombinant viruses and importantly much less prone to off-target mutagenesis than other genetic modification technologies. In a previous clinical trial, CoImmune’s CAR-CIK product for B cell malignancies demonstrated strong clinical efficacy with little to no toxicity.

Solid tumors constitute 95% of the cancer market. Compared to B cell malignancies, CAR-T cells have been shown to be poorly effective against solid tumors due in part to the hostile tumor microenvironment and risk of significant safety issues associated with off-target effects. These new technologies are designed to improve CAR-CIK functionality in the tumor microenvironment and improve the persistence of the allogeneic cells, and were developed by David A. Scheinberg, MD, PhD, Chair of the Sloan Kettering Institute’s Molecular Pharmacology Program and Director of MSK’s Experimental Therapeutics Center, Derek S. Tan, PhD, Chair of the Sloan Kettering Institute’s Chemical Biology Program, and Renier J. Brentjens, MD, PhD, now Deputy Director and Chair of Medicine, Roswell Park Comprehensive Cancer Center.

As a result of the licensing arrangement noted in this release, MSK has institutional financial interests in the technologies and in CoImmune. Drs. Scheinberg, Tan, and Brentjens have intellectual property interests related to the technologies referenced in this release. Additionally, Drs. Scheinberg and Tan have other financial interests related to CoImmune.

About CoImmune, Inc.
CoImmune is a privately held, clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class cellular immunotherapies. Our allogeneic CAR-CIK technology platform for liquid and solid tumors is a variation on CAR-T therapy that is designed to enhanced efficacy with greatly reduced toxicity. Our autologous RNA-loaded dendritic cell technology for solid tumors uses amplified total tumor mRNA to program highly engineered dendritic cells to generate immune responses against neoantigens without the need to identify them.

Investor Contact:
Lori Harrelson
Chief Financial Officer
CoImmune, Inc.
lharrelson@coimmune.com

Media Contact:
Bill Berry
Berry & Company Public Relations
bberry@berrypr.com
212.253.8881

Posted on

BRIN builds genomics research center for life, environmental science

The National Research and Innovation Agency (BRIN) has built a genomics building at the Cibinong Science Center, West Java, which will be utilized for whole-genome sequencing, life science, and environmental research.

“This building for genomic studies will later be used as a whole-genome sequencing laboratory for microbes, plants, animals, and humans, life science, and environmental research,” BRIN head Laksana Tri Handoko said in a written statement received here on Monday.

The genomic research building spans 9,300 square meters and will be useful to support research activities, especially in the field of life sciences, he highlighted.

Cibinong Science Center has several facilities and complete infrastructure to support research in life sciences study, such as molecular biology, he said.

Although so far the research facility at Cibinong Science Center has been more focused on biodiversity research, it shares similarities with research on health and humans at the Eijkman Institute for Molecular Biology, Handoko said.

Many research centers and researchers at Cibinong Science Center, such as biotechnology research center, biodiversity center, and Indonesian Culture Collection (InaCC) for microbes, are carrying out relevant work, he added.

BRIN’s acting deputy for research and innovation infrastructure, Yan Rianto, said the genomic building built by BRIN is now complete.

Some laboratory equipment has also arrived and will soon be installed, such as a 50-liter capacity fermentor that can be used for research and development of the COVID-19 vaccine, he added.

“While the electricity infrastructure is planned to be installed next week,” Rianto informed.

BRIN, as the government agency for science innovation and research, has been advancing its work by providing facilities in many fields of research, he said. One of them is developing innovations in the livestock sector to support productivity, he added.

The agency is also focusing on research in mitigating diseases, such as malaria, and coming up with ideas in using technology to bolster the nation’s readiness in facing natural disasters, he said.

Source: Antara News

Posted on

Bekasi District close to achieving 70% vaccination coverage

With 69.44 percent of its population receiving the first coronavirus vaccine dose, Bekasi District is close to achieving herd immunity, the district’s COVID-19 task force has said.

 

“We hope to achieve herd immunity soon as we have administered the first vaccine dose to 69.44 percent of the district’s residents as of last Sunday (October 17, 2021),” Deputy Spokesperson of Bekasi District’s COVID-19 Task Force Masrikoh informed in Cikarang, here on Monday.

 

Based on the latest data, the first vaccine dose has been administered to 1,678,894 residents, or 69.44 percent of the total 2,417,794 residents targeted for vaccinations, she said.

 

The deputy spokesperson expressed confidence the district would reach the 70-percent vaccination coverage prerequisite laid down by the World Health Organization (WHO) for achieving herd immunity status at the end of October 2021.
“We need support from stakeholders to expedite the vaccination effort, and unvaccinated residents should immediately register for the vaccination in their localities,” Masrikoh said.

 

Around 996,801 residents, or 41.23 percent of the targeted recipients, have received their second vaccine dose, she added.

 

Of the total 296,174 teenagers in the 12-17 age group targeted for vaccination, 111,328 have received their first vaccine dose and 94,655 have completed their second dose, the deputy spokesperson informed.

 

Seventy percent vaccination coverage is the main prerequisite to improve the activities restriction enforcement (PPKM) status in the district, currently designated at level 3, to level 2, Masrikoh said.
“Cities within the Jabodetabek agglomeration area are currently assisting each other on pandemic control, and I am convinced they all are exerting their utmost effort to increase the vaccination coverage in their cities,” she added.

 

The Bekasi authorities are committed to expediting vaccination coverage by all means possible, including hosting vaccination drives at public locations, collaborating with midwives, and hosting vaccinations on boats to ensure vaccine coverage in the remotest areas of the district, she affirmed.

Source: Antara News

Posted on

BRIN facilitates utilization of technology in farming for public

The National Research and Innovation Agency (BRIN) facilitates the use of technology, such as in the farming sector, for the people, so that they can reap substantial benefits.

“The BRIN will introduce applicative technology in accordance with the potential and the need of people in the region,” BRIN’s official, Satriyo Krido Wahono, noted in a written statement that ANTARA received here on Monday.

The BRIN will introduce the use of technology, such as for the development of locally sourced livestock feed as well as for the utilization of livestock produce for economic benefits, he noted.

The farming industry is one of the sectors that supports Indonesia’s economy, especially for agrarian people in villages, he explained.
Hence, Wahono opined that the use of technology is expected to boost the people’s productivity and performance.

Meanwhile, BRIN’s researcher, Andi Febrisiantosa, introduced the concept of integrated farming to the people.

This step was taken in a bid to manage the input of technological innovation-based farming that can be economically beneficial, socially and culturally acceptable, and environmentally friendly.

“This concept of integrated farming can produce food, feed, organic fertilizer, energy fuel, and waste that can be processed,” he elaborated.

Thus far, BRIN has developed livestock product technology for food requirement, biogas technology that produces organic fertilizer, and poultry and ruminants feed technology, he outlined.
Febrisiantosa also introduced the forage preservation technique with silage system by conducting controlled fermentation for plants with high amount of water, egg processing technology, and meat packaging.

“These technologies are quite easy to use since they use local ingredients that are not hard for farmers to obtain,” Febrisiantosa noted.

BRIN, along with the House of Representatives (DPR) Commission VII member, held an Integrated Farming Technology Technical Guideline at Mrebet Village, Purbalingga District, Central Java, on Saturday.

Source: Antara News

Posted on

2021 Human Rights Festival reflects government’s commitment: Official

Deputy V of the Presidential Staff Office Jaleswari Pramodhawardani affirmed that the 2021 Human Rights Festival is a form of the government’s commitment to realizing human rights-friendly districts and cities.

She highlighted the Presidential Staff Office’s enthusiasm to become involved in the event, initiated by the International NGO Forum on Indonesian Development (INFID) and National Commission on Human Rights (Komnas HAM).

“In his speech commemorating International Human Rights Day 2020, President Jokowi once again lauded the initiative of the Human Rights Festival, which is actually a district or city festival, as an effort to mainstream the implementation and responsibilities of human rights in the regions,” Pramodhawadani stated after signing the cooperation agreement and opening the 2021 Human Rights Festival in Semarang, Central Java on Monday, according to a press release received here.

The 2021 Human Rights Festival will be hosted both online and offline on November 16-19, 2021, in Semarang. The festival, themed “Moving Together, Strengthening Diversity, Inclusion, and Resilience,” is expected to be a common force to win the war against COVID-19 and rise and grow to realize Indonesia’s 2045 vision.

Pramodhawadani noted that local governments were at the frontline of human rights issues, as they had greater knowledge of the everyday dynamics of village residents.

“The local government’s physical closeness and engagement with residents must be utilized by expediting dialogue towards substantive citizen participation,” she emphasized.

She assessed that the local government had, so far, made all-out efforts and succeeded in solving the human rights problems in the community. For instance, the completion of permits for the establishment of the Indonesian Baptist Church in Tlogosari, Semarang City, and the establishment of Church (GKJTI) in Jepara District and Church (GKI) Yasmin in Bogor City, West Java.

“I feel it is important to highlight good practices such as these in the hopes of serving as an inspiration to regional heads and all stakeholders,” she remarked.

She lauded all stakeholders involved in the preparation and implementation of the 2021 Human Rights Festival.

She expects the agenda to serve as a forum for local governments and human rights stakeholders to support and inspire one another while stressing on the notion that the state still existed in the midst of a pandemic to protect and fulfill the rights of citizens.

Source: Antara News

Posted on

Ministry details efforts to protect Indonesians from death penalty

The Foreign Affairs Ministry has detailed efforts made by the government to protect Indonesian citizens (WNI) from the death penalty abroad.

“There are three principles that we adhere to protect Indonesian citizens which are regulated in the Minister of Foreign Affairs’ Regulation Number 5 of 2018,” Director for the Protection of Citizens and Legal Entities Overseas at the Ministry of Foreign Affairs, Judha Nugraha, said here on Monday.

The first is prioritizing the responsible parties, he said. Second, the government does not take any criminal or civil responsibility, he added. Lastly, the protection is provided in accordance with national law, local state law, and customary international law, he continued.

“We do not give impunity to our citizens who commit crimes abroad, but the duty of our state is to provide legal assistance,” Nugraha remarked.

The legal assistance is intended to ensure Indonesian citizens facing legal action in other countries have fair access to their rights, he said.

Efforts to protect Indonesian citizens from the death penalty in foreign countries also depend on the country imposing the sentence, he added. For example, Saudi Arabia and Middle Eastern countries usually refer to Islamic law, he explained.

“In Islamic countries, there are three types of murder cases, namely hadd, takzir, and kisas,” Nugraha said.

However, murder cases in those countries are generally included in kisas, he added. For kisas, there is an apology mechanism that is carried out or given by the victim’s family, he elaborated.

In addition, the state has also made a number of other efforts to help Indonesian citizens in foreign countries encountering problems with the law through litigation and non-litigation steps, he said.

Legal efforts taken include consular access, appointment of lawyers and translators, and other efforts according to the law in the local country, he informed.

Diplomatic efforts include diplomacy at the bilateral level through lobbying or diplomatic notes and approaching the sultan or the local state government, he said.

The government can also approach the victim’s family, provide moral support, and campaign for public awareness, he added.

Source: Antara News

Proudly powered by WordPress